Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial

Table 3 Number of adverse events per treatment group ^a

^aAE, Adverse event; COBRA Slim, COmbinatie therapie bij Reumatoïde Artritis; MTX-TSU, Methotrexate with tight step-up, 15 mg of MTX weekly, no oral steroids allowed. Protocol determines the severity rating of the adverse event: mild (does not interfere with daily living), moderate (somewhat interferes with daily living or medications needed to relieve event) or severe (incapacitating).

ISSN: 1478-6362